• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Respiratorius

2.30 SEK

0.00 %

Less than 1K followers

RESP

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
0.00 %
-16.67 %
+72.93 %
+41.98 %
+39.39 %
-71.25 %
-90.61 %
-97.22 %
-83.93 %

Respiratorius is a research company focused on the development of drug candidates for the treatment of cancer, and especially aggressive lymphoma. The company was established in 1999 as a spin-off from Lund University. The operations are located in Sweden, where research is conducted in-house, but also through international partners. The company has its headquarters in Lund.

Read more
Market cap
18.18M SEK
Turnover
104.2 SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
All
Press releases
ShowingAll content types

Financial calendar
11.8
2026

Interim report Q2'26

10.11
2026

Interim report Q3'26

9.2
2027

Annual report '26

Regulatory press release9/1/2025, 6:32 AM

Respiratorius Receives Meeting Minutes from FDA Pre-IND Meeting

Respiratorius
Regulatory press release8/12/2025, 6:30 AM

Respiratorius has conducted a pre-IND meeting with the FDA

Respiratorius
Regulatory press release6/18/2025, 6:18 AM

Respiratorius Granted Pre-IND Meeting with FDA for VAL001

Respiratorius

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/27/2025, 12:33 PM

Respiratorius: Notice of Allowance for European Patent on VAL001 Formulation

Respiratorius